Physician profile
Abigail C Brubaker
NPI 1831536911
$2,244.87
in general payments reported to CMS, 2019-2025
27 companies · $460 in 2025
The $460 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.28 · 2020: $159 · 2021: $201 · 2022: $436 · 2023: $624 · 2024: $272 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,356.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $478.43 | 2019-2025 | Liletta, Lo Loestrin Fe, Synthroid |
| Organon LLC | $250.62 | 2021-2025 | Nexplanon, Jada System |
| Hologic Sales and Service, LLC | $243.96 | 2021-2025 | Myosure Tissue Removal Device, Aptima, Thinprep 2000 Processor |
| Mayne Pharma Commercial LLC | $165.26 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $156.77 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $143.13 | 2020-2024 | Gardasil 9, Gardasil |
| Sumitomo Pharma America, INC. | $123.74 | 2023-2025 | Myfembree |
| Exeltis, USA INC. | $110.01 | 2020-2025 | Slynd |
| Astellas Pharma US INC | $84.68 | 2023-2025 | Veozah |
| Therapeuticsmd, INC. | $70.79 | 2019-2022 | |
| Coopersurgical, INC. | $62.63 | 2021-2023 | Paragard T 380a |
| Ascend Therapeutics US, LLC | $46.74 | 2021-2022 | |
| Dexcom, INC. | $32.89 | 2025 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $29.17 | 2020 | |
| Convatec INC. | $28.31 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $27.92 | 2023-2024 | Quviviq |
| Smith+Nephew, INC. | $25.11 | 2025 | Pico |
| Cepheid | $20.64 | 2024 | |
| Medicem INC. | $19.00 | 2023 | |
| Amgen INC. | $18.76 | 2022 | |
| Millicent US INC | $17.69 | 2025 | Intrarosa, Femring |
| Avion Pharmaceuticals | $16.88 | 2022 | |
| Intuitive Surgical, INC. | $15.59 | 2024 | |
| Agile Therapeutics, INC. | $14.82 | 2023 | Twirla |
| Gynesonics, INC. | $14.39 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Aspira Women'S Health INC | $14.20 | 2020 | |
| Lupin INC. | $12.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Brubaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.